Today for AI
HOT RADAR
industryHEAT 15.5°

AI CURATED HOT STORY · 11/5/2026

Alphabet's Isomorphic Labs in Talks to Raise $5B at $50B Valuation

1 reports archived1 independent sourcesupdated 11/5/2026, 09:16:45
Synthesis & Latest Updates
1 Sources Cross-Validated

Bloomberg reports that Isomorphic Labs, the Alphabet unit spun out of Google DeepMind, is negotiating a roughly $5B raise at about a $50B valuation, despite having no drug yet tested in humans. Its core asset is a drug-design engine built on AlphaFold 3 that predicts protein folding and how candidate molecules bind their targets, letting chemists rank and discard weak designs on a computer before paying for synthesis and animal studies. Without human data, the $50B price rests on prediction accuracy and pharma partnerships rather than evidence that its molecules work in patients.

LATEST/Bloomberg reports that Isomorphic Labs, the Alphabet unit spun out of Google DeepMind, is negotiating a roughly $5B raise at about a $50B valuation, despite having no drug yet tested in humans. Its core asset is a drug-design engine built on AlphaFold 3 that predicts protein folding and how candidate molecules bind their targets, letting chemists rank and discard weak designs on a computer before paying for synthesis and animal studies. Without human data, the $50B price rests on prediction accuracy and pharma partnerships rather than evidence that its molecules work in patients.

Coverage timeline

Total 1 reports · Latest first
  1. Rohan Paul (@rohanpaul_ai)T2·67 pts

    Alphabet's Isomorphic Labs in Talks to Raise $5B at $50B Valuation

    • Isomorphic Labs is negotiating a roughly $5B raise at about a $50B valuation with no drug yet in human trials.
    • Its engine is built on AlphaFold 3 to predict protein folding and candidate-molecule binding, enabling in-silico screening before wet-lab work.
    • The valuation rests on prediction accuracy and pharma partnerships rather than clinical evidence of efficacy.
    • If completed, the deal becomes a key signal for how the market prices AI drug discovery.